Loss of heterozygosity is related to p53 mutations and smoking in lung cancer

S Zienolddiny, D Ryberg, MO Arab, V Skaug and A Haugen

Department of Toxicology, National Institute of Occupational Health, P.O. Box 8149 Dep., N-0033 Oslo, Norway

Summary Carcinogenesis results from an accumulation of several genetic alterations. Mutations in the p53 gene are frequent and occur at an early stage of lung carcinogenesis. Loss of multiple chromosomal regions is another genetic alteration frequently found in lung tumours. We have examined the association between p53 mutations, loss of heterozygosity (LOH) at frequently deleted loci in lung cancer, and tobacco exposure in 165 tumours from non-small cell lung cancer (NSCLC) patients. A highly significant association between p53 mutations and deletions on 3p, 5q, 9p, 11p and 17p was found. There was also a significant correlation between deletions at these loci. 86% of the tumours with concordant deletion in the 4 most involved loci (3p21, 5q11–13, 9p21 and 17p13) had p53 mutations as compared to only 8% of the tumours without deletions at the corresponding loci (P < 0.0001). Data were also examined in relation to smoking status of the patients and histology of the tumours. The frequency of deletions was significantly higher among smokers as compared to non-smokers. This difference was significant for the 3p21.3 (hMLH1 locus), 3p14.2 (FHIT locus), 5q11–13 (hMSH3 locus) and 9p21 (D9S157 locus). Tumours with deletions at the hMLH1 locus had higher levels of hydrophobic DNA adducts. Deletions were more common in squamous cell carcinomas than in adenocarcinomas. Covariate analysis revealed that histological type and p53 mutations were significant and independent parameters for predicting LOH status at several loci. In the pathogenesis of NSCLC exposure to tobacco carcinogens in addition to clonal selection may be the driving force in these alterations. © 2001 Cancer Research Campaign http://www.bjcancer.com

Keywords: non-small cell lung cancer; LOH; p53 mutations; smoking; DNA-adducts

Mutations in p53 are among the most frequent genetic alterations detected in lung cancer and are acquired early in the development of the disease (Bennett et al, 1993; Bennett, 1995). In non-small cell lung cancer (NSCLC) about half of the tumours carry mutations in the p53 gene (Takagi et al, 1998). The prevalent type of mutation is G:C → T:A transversion which is related to DNA adducts of benzo(a)pyrene from cigarette smoking (Greenblatt et al, 1994; Denissenko et al, 1996). p53 plays an important role in preserving genomic stability through controlling the cell cycle checkpoints (Hartwell, 1992). Both human and mouse cells homozygous for p53 mutations are genetically unstable and show high rates of homologous recombination (Livingstone et al, 1992; Yin et al, 1992; Mekel et al, 1997). Other potential tumour suppressor genes are localized on chromosomes 3p, 5q, 9p and 11p (Kohno et al, 1999). It has been shown that deletions of chromosome 3p are early events in the development of the disease, and such changes are often observed in lung tumours (Wistuba et al, 1997). The FHIT gene at 3p14.2 has been shown to be a target of carcinogens in the tobacco smoke (Sozzi et al, 1997). The hMLH1 gene maps to 3p21.3 and a high frequency of loss of heterozygosity (LOH) has been shown at this locus in lung cancer (Benachenhou et al., 1998). A concordant LOH of hMLH1 locus and the hMSH3 locus at 5q11–13 has been reported (Benachenhou et al., 1998). Mutations in the mismatch repair genes (MMR) are associated with a distinct molecular phenotype known as microsatellite instability (MSI) (Eshleman and Markowitz, 1996). In lung cancer, the majority of studies have reported a low level (<5%) of MSI (Benachenhou et al, 1998). However, studies have shown that defects in DNA repair may be a predisposing factor in lung cancer (Wei and Spitz, 1997).

Lung cancer is characterized by multiple genetic changes (Gazdar, 1994). A relationship between p53 mutations and 3p deletions has been reported in lung cancer (Horio et al, 1993; Burke et al, 1998; Kohno et al, 1999). The purpose of this study was to explore the association between tobacco exposure, p53 mutations and concordant LOH at several loci harbouring potential tumour suppressor genes involved in lung cancer.

MATERIALS AND METHODS

Tissue samples

Surgically resected tumours and corresponding normal lung tissue were obtained from 165 lung cancer patients. The majority of tumours were at stage I according to international TNM staging. Each tissue was snap-frozen after surgery and stored at –80°C.

Prior to DNA isolation the tumour tissues were freeze-sectioned. 5–10 sections of each sample were stained with eosin and haematoxylin. Based on these slides, the tumours were trimmed to obtain tissue samples including information on smoking habits. The characteristics of the lung cancer patients are summarized in Table 1.

Analysis of LOH using microsatellite markers

17 polymorphic dinucleotide (CA) repeats representing regions with known DNA repair genes or tumour suppressor genes were detected in lung cancer patients.
The hypothesis of independence in LOH at the 4 most involved loci was tested using likelihood ratio test with correction for continuity. Logistic regression analysis (SPSS v. 10) was used to identify important variables predicting LOH and to calculate adjusted \( P \) values. The following variables were included in the model: \( p53 \) mutational status, smoking status, gender, age and histological types. \( p53 \) mutational status and histological types were the only significant parameters predicting LOH status at most of the loci. Since the number of non-smoker patients was low in this study, the association between smoking status and LOH status was analysed using Fishers exact test. The relationship between PAH adduct levels and LOH status was analysed by Wilcoxon rank sum test. The StatXact version 4 program was used for trend analysis.

### RESULTS

Paired tumour/normal DNA samples from 165 NSCLC patients (Table 1) were examined for allelic imbalance at 17 polymorphic microsatellite markers in 7 different chromosomes. High LOH frequencies (about 50%) were observed with 3p, 5q, 9p and 17p markers, moderate LOH at 11p15, and low frequencies at 7p and 2p loci (Table 2). There was a significant correlation between deletions in markers at 3p, 5q, 9p, 11p and 17p loci (data not shown). The concordant LOH at the 4 most deleted loci 3p21, 5q11–13, 9p21 and 17p13 based on data from the markers D3S1611-D3S1612, D5S431, D9S157 and TP53-D17S786, respectively, was further examined. 83 cases were informative for all these 4 loci; 14 cases were deleted at all 4 loci, 21 deleted at 3 loci, 14 at 2 loci, 9 at one locus, and 25 cases had retained heterozygosity at all 4 loci. The corresponding expected frequencies based on independence would be 4.5, 19.3, 31.1, 22.2 and 5.9 cases. This difference in the observed and expected frequencies of concordant LOH at the 4 loci was statistically significant and the possibility that these deletions may have occurred independently should be rejected (\( P = 0.03 \times 10^{-5} \), likelihood ratio test with correction for continuity). Similar results were obtained using other markers at 3p, 5q and 17p. Of 115 cases informative for \( hMLH1 \) (D3S1611-D3S1612) and \( hMSH3 \) (D5S431), 47 (41%) were deleted

### Statistical methods

The hypothesis of independence in LOH at the 4 most involved loci was tested using likelihood ratio test with correction for continuity. Logistic regression analysis (SPSS v. 10) was used to identify important variables predicting LOH and to calculate adjusted \( P \) values. The following variables were included in the model: \( p53 \) mutational status, smoking status, gender, age and histological types. \( p53 \) mutational status and histological types were the only significant parameters predicting LOH status at most of the loci. Since the number of non-smoker patients was low in this study, the association between smoking status and LOH status was analysed using Fishers exact test. The relationship between PAH adduct levels and LOH status was analysed by Wilcoxon rank sum test. The StatXact version 4 program was used for trend analysis.

### Table 1

| Parameter | Total | Mean (95% CI) |
|-----------|-------|--------------|
| Total     | 165   |              |
| Male      | 122   | (73.9)       |
| Female    | 43    | (26.1)       |
| Histological subtype |       |              |
| Adenocarcinoma | 69 | (41.8)           |
| Squamous cell carcinoma | 68 | (41.2)           |
| Other     | 28    | (17.0)       |
| Age       |       | 62.1 (60.4–63.9) |
| Smoking history |       |              |
| Smokers   | 147   | (89.1)       |
| Cigarettes per day | 15.6 | (14.4–16.7) |
| Pack-years | 30.7 | (28.1–33.4) |
| Years of smoking | 39.6 | (37.4–41.7) |
| Non-smokers | 15   | (9.1)         |
| Unknown   | 3     | (1.8)        |

CI, confidence interval; *Other includes unknown, large cell and small cell (2 cases) carcinomas; †Not smoked for the past 20 years.

### Table 2

| Marker | Informative cases n (%) | LOH* n (%) |
|--------|-------------------------|------------|
| D2S123 | 127 (77.4)               | 19 (15.0)  |
| D2S391 | 123 (75.0)               | 15 (12.2)  |
| D3S1611| 109 (66.1)               | 51 (46.8)  |
| D3S1612| 117 (71.3)               | 55 (47.0)  |
| D3S966 | 128 (77.6)               | 61 (47.7)  |
| D3S1289| 144 (87.3)               | 66 (45.8)  |
| D3S1500| 136 (82.4)               | 64 (47.1)  |
| D5S1968| 126 (76.8)               | 56 (44.4)  |
| D5S2089| 134 (81.7)               | 56 (41.8)  |
| D5S431 | 131 (79.4)               | 60 (45.8)  |
| D5S495 | 109 (66.5)               | 45 (41.3)  |
| D7SS51 | 134 (81.2)               | 18 (13.4)  |
| D9S157 | 136 (82.9)               | 65 (47.6)  |
| D11S181| 124 (79.5)               | 45 (36.2)  |
| D17S799| 123 (75.0)               | 61 (49.6)  |
| D17S786| 122 (73.9)               | 62 (50.8)  |
| TP53   | 73 (44.5)                | 33 (45.2)  |

*LOH = no. of cases with deletions/no. of informative cases.

© 2001 Cancer Research Campaign

British Journal of Cancer (2001) 84(2), 226–231
at both loci. However, this was not specific for these 2 loci since similar frequencies were found at other loci investigated.

The p53 mutations were found in 86 (52%) of the 165 tumours analysed (Kure et al, 1996; Skaug et al, 2000). Using logistic regression and adjusting for other variables there was a significant association between the presence of p53 mutations and occurrence of LOH at 3p, 5q, 9p, 11p and 17p (Table 3). Similar results were also obtained when smoking status was replaced by smoking years or pack-years in the logistic models. Of the 14 cases with concordant LOH at the 4 most deleted regions (see above), 12 (85.7%) had mutations in the p53 gene. The corresponding frequency of mutations in the 25 tumours without LOH in these loci was only 2 (8%) ($P < 0.0001$, Fishers exact test). There was also a significant correlation between the frequency of p53 mutations and the number of loci deleted (Figure 1, $P < 0.0001$ trend test). Of 47 cases deleted in both hMLH1 and hMSH3 loci, 37 (79%) had p53 mutations whereas only 11 (22%) of the 49 cases without LOH were mutated in p53 ($P < 0.0001$, Fisher exact test). The LOH data were also analysed with respect to p53 mutational types and positions without any particular findings.

The frequency of LOH was significantly lower in non-smokers as compared to smokers for the hMLH1 locus, D3S1300 (FHIT), D5S431 (hMSH3), and D9S157 using table analysis and Fishers exact test (Table 4). Using logistic regression and adjusting for p53 mutational status, histological types, age and gender only the D9S157 marker gave significant association. Since the number of non-smokers is low and p53 mutations are nearly absent among non-smoking patients, the last method is less reliable. Tumours deleted in the hMLH1 locus showed higher PAH-DNA adduct levels ($P = 0.078$, Wilcoxon rank test) and there were more tumours with LOH in this locus in the upper adduct tertile ($\geq 12.36$ adducts/10$^8$ nucleotides) than in the lower tertile group ($\leq 6.67$ adducts/10$^8$ nucleotides, $P = 0.06$, Fisher’s exact test). Other loci on 3p showed similar tendency, but the statistics were weaker.

The frequency of LOH was significantly higher in squamous cell carcinomas compared to adenocarcinomas for several loci after adjusting for p53 mutational status, smoking status, gender and age (Table 5). Similar results were seen when smoking years and pack-years replaced smoking status in the logistic models. Among the 14 tumours with LOH at all the 4 most involved loci, 9 (64.3%) were squamous cell carcinomas and 3 (21.4%) were adenocarcinomas.

**DISCUSSION**

Lung tumours harbour several genetic abnormalities including p53 mutations and loss of several chromosomal regions. In this study we have examined possible interactions between several genetic alterations in the tumours, particularly at loci with potential tumour suppressor genes.

Analysis of the sequence of abnormalities in lung cancer has shown that deletions in the 3p region are early events and precede deletions in 9p, 17p (TP53 locus) and 5q (Wistuba et al, 1999).

![Figure 1 Correlation between incidence of p53 mutations and number of loci deleted in tumours informative for all the 4 loci, 3p21, 5q11–13, 9p21 and 17p13. Figures in ( ) indicate no. of informative cases. Trend test: $P = 0.0001$](image)

**Table 3** Frequencies of LOH at individual locus in relation to mutational status of the p53 gene

| p53 gene status | 2p16–21 (D2S123– D2S391)$^a$ | 3p21.3 (D3S1611– D3S1300) | 3p14.2 (D3S431) | 5q11–13 (D5S495) | 7p22 (D7S331) | 9p21 (D9S157) | 11p15 (D11S4181) | 17p13 (TP53– D17S786)$^a$ |
|-----------------|----------------------|-------------------------|-----------------|-----------------|-----------------|-----------------|---------------------|----------------------|
| Mutated         | 11/72                | 52/76                   | 44/71           | 44/66           | 31/56           | 10/72           | 17/62               | 11/59                |
| Normal          | 5/71                 | 20/69                   | 20/65           | 16/65           | 14/53           | 8/62            | 17/62               | 11/59                |
| $P^b$           | NS                   | 0.001                   | 0.03            | 0.001           | 0.04            | NS              | 0.0003              | 0.002                |

$^a$LOH at one or both markers. $^b$P-values based on logistic regression adjusting for smoking status, gender, age and histological types. NS – not significant.

**Table 4** Frequency of LOH in smokers and non-smokers

| Chromosome | 2p16–21 (D2S123– D2S391)$^a$ | 3p21.3 (D3S1611– D3S1300) | 3p14.2 (D3S431) | 5q11–13 (D5S495) | 7p22 (D7S331) | 9p21 (D9S157) | 11p15 (D11S4181) | 17p13 (TP53– D17S786)$^a$ |
|------------|----------------------|-------------------------|-----------------|-----------------|-----------------|-----------------|---------------------|----------------------|
| Smokers$^b$| 25/134               | 70/129                  | 63/124          | 59/115          | 43/99           | 16/121          | 63/121              | 38/105               |
| Non-smokers$^b$ | 0/15               | 2/14                    | 1/10            | 1/12            | 2/7             | 2/11            | 1/14                | 3/14                 |
| P (Fishers exact test) | 0.08               | 0.005                   | 0.02            | 0.005           | NS              | NS              | NS                  | NS                   |

$^a$LOH at one or both markers; NS – not significant.

*British Journal of Cancer (2001) 84(2), 226–231 © 2001 Cancer Research Campaign*
Further deletion mapping of the 3p region has revealed chromosomal regions 3p21 and 3p14 to be most frequently deleted in many cancer types including NSCLC (Mitsudomi et al, 1996; Todd et al, 1997; Benachenhou et al, 1998; Nelson et al, 1998). The relationship between allelic losses at the various loci, may indicate an interaction between various genes(s) in these loci during the process of clonal selection.

The high frequency of deletions found at the hMLH1 and hMSH3 loci may indicate a possible role for these loci in NSCLC. A possible interdependence of LOH at these loci has been indicated (Benachenhou et al, 1998). This study confirmed concomitant LOH in cases informative for both loci. However, a similar concomitant LOH frequency was also found when other frequently affected regions were investigated. Similar LOH frequencies were also observed for other markers within the 3p region and 5q region indicating an interaction between several genes, not specifically on 3p21 and 3q11–13. The unexpectedly high number of tumours without apparent LOH at the 4 most involved loci at 3p21, 3q11–13, 9p21 and 17p13 (25 cases against the expected 5.9 cases) may indicate that specific mechanisms are involved, resulting in frequent deletions in all these loci. DNA repair genes like hMLH1 and hMSH3, and the p53 gene may be involved in these mechanisms. Deficiencies in MMR genes are associated with several cancers often resulting in MSI in tumours (Lengauer et al, 1997). MSI in lung cancer occurs at a low frequency (Benachenhou et al, 1998). However, MMR proteins are involved in a variety of other cellular processes such as homologous recombination (de Wind et al, 1995), mediation of the G2 checkpoint (Meyers et al, 1997; Walker et al, 1999). Hotspot somatic mutations in cancers may represent protein alterations which provide a selective growth advantage to the cell. Genomic instability in a subset of non-smoking lung cancer patients has been related to mutations in the p53 gene (Pellegrini et al, 1999). Genomic instability induced by p53 may arise through abnormal cell cycle check points (Hartwell, 1992). Considering the involvement of both p53 and MMR genes in cell cycle, an interaction between them in maintaining genomic stability may seem reasonable. However, no correlation between MSI and p53 mutations has been found in NSCLC (Caligo et al, 1998). Other pathways such as recombination have also been reported to be involved in induction of LOH in normal human cells (Gupta et al, 1997) and loss of both alleles of p53 in a primary human glioblastoma tumour and cell line (Albertoni et al, 1998).

For all loci examined (except 7p), there was a clear trend of higher occurrence of LOH in smokers than non-smokers. While number of cases with LOH was significantly lower among non-smokers in both regions of 3p (3p 14.2 and 3p21), this was only significant for the 5q11–13 (hMSH3 locus) locus on chromosome 5q. Despite the low number of non-smoking cases, this may indicate a possible association between smoking and occurrence of LOH. The differences in association of LOH with the smoking status may suggest that the genetic loci may differ in their sensitivity to the mutagenic effects of carcinogens. Associations between cigarette smoking and FHIT gene (3p14.2) alterations have been reported (Sozzi et al, 1997; Tomizawa et al, 1998). Deletions within the LOH11B locus on 11p have also been associated with high cigarette consumption (Schreiber et al, 1997). Significantly higher p53 mutations in tumours and PAH-DNA adduct levels in lung tissue are observed in smoking than non-smoking lung cancer patients (Ryberg et al, 1994a, 1994b). The higher frequency of tumours with LOH in 3p21.3 locus in the upper adduct tertile may indicate a higher sensitivity of this locus to tobacco carcinogens. An association of increased 3p21 LOH with increasing PAH-DNA adducts in squamous cell carcinomas of the lung has recently been reported (Hirao et al, 2000) and Wu et al, (1998) demonstrated a dose–response relationship between BPDE exposure and 3p21.3 (hMLH1 region) aberrations in lymphocytes from lung cancer patients.

Adenocarcinoma and squamous cell carcinoma are the two major histological types found in NSCLC. This study showed that mutations had mutations in reported hotspot codons (9p21) and other genes at 17p (3p14.2), mutations and LOH in NSCLC mutations in tumours and PAH-mutations may arise through loci may indicate a possible role for these loci in NSCLC.

### Table 5

| Histological subtype | 2p16–21 | 3p21.3 | 3p14.2 | 5q11–13 | 5q21 | 7p22 | 9p21 | 11p15 | 17p13 |
|----------------------|---------|--------|--------|---------|------|------|------|-------|-------|
| Adenocarcinoma       | 8/60    | 22/59  | 20/53  | 17/55   | 11/46| 6/56 | 26/58| 19/55 | 27/60 |
| Squamous cell        | 3/61    | 40/62  | 35/62  | 33/53   | 23/42| 8/54 | 29/53| 19/46 | 34/60 |

P<0.0001, trend test) toward increased frequency of LOH with the higher number of loci deleted, may further support a relationship between these two types of genetic alterations. Among samples with concordant LOH at the 4 most deleted loci all 12 samples with p53 mutations had mutations in reported hotspot codons (Walker et al, 1999). Hotspot somatic mutations in cancers may represent protein alterations which provide a selective growth advantage to the cell. Genomic instability in a subset of non-smoking lung cancer patients has been related to mutations in the p53 gene (Pellegrini et al, 1999). Genomic instability induced by p53 may arise through abnormal cell cycle check points (Hartwell, 1992). Considering the involvement of both p53 and MMR genes in cell cycle, an interaction between them in maintaining genomic stability may seem reasonable. However, no correlation between MSI and p53 mutations has been found in NSCLC (Caligo et al, 1998). Other pathways such as recombination have also been reported to be involved in induction of LOH in normal human cells (Gupta et al, 1997) and loss of both alleles of p53 in a primary human glioblastoma tumour and cell line (Albertoni et al, 1998).

For all loci examined (except 7p), there was a clear trend of higher occurrence of LOH in smokers than non-smokers. While number of cases with LOH was significantly lower among non-smokers in both regions of 3p (3p 14.2 and 3p21), this was only significant for the 5q11–13 (hMSH3 locus) locus on chromosome 5q. Despite the low number of non-smoking cases, this may indicate a possible association between smoking and occurrence of LOH. The differences in association of LOH with the smoking status may suggest that the genetic loci may differ in their sensitivity to the mutagenic effects of carcinogens. Associations between cigarette smoking and FHIT gene (3p14.2) alterations have been reported (Sozzi et al, 1997; Tomizawa et al, 1998). Deletions within the LOH11B locus on 11p have also been associated with high cigarette consumption (Schreiber et al, 1997). Significantly higher p53 mutations in tumours and PAH-DNA adduct levels in lung tissue are observed in smoking than non-smoking lung cancer patients (Ryberg et al, 1994a, 1994b). The higher frequency of tumours with LOH in 3p21.3 locus in the upper adduct tertile may indicate a higher sensitivity of this locus to tobacco carcinogens. An association of increased 3p21 LOH with increasing PAH-DNA adducts in squamous cell carcinomas of the lung has recently been reported (Hirao et al, 2000) and Wu et al, (1998) demonstrated a dose–response relationship between BPDE exposure and 3p21.3 (hMLH1 region) aberrations in lymphocytes from lung cancer patients.

|  | D2S391 | a | D3S1612 | a | D17S786 | a |  |  |
|-------------------|--------|---|---------|---|---------|---|---|---|
| Frequencies of LOH at individual locus in relation to the two major histological types |  |  |  |  |  |  |  |  |
| **Histological subtype** | **2p16–21** (D2S123–D2S391) | **3p21.3** (D3S161–D3S1612) | **3p14.2** (D3S1300) | **5q11–13** (D5S431) | **5q21** (D5S495) | **7p22** (D7S531) | **9p21** (D9S157) | **11p15** (D11S4181) | **17p13** (TP53–D17S786) |
| Adenocarcinoma | 8/60 | 22/59 | 20/53 | 17/55 | 11/46 | 6/56 | 26/58 | 19/55 | 27/60 |
| Squamous cell | 3/61 | 40/62 | 35/62 | 33/53 | 23/42 | 8/54 | 29/53 | 19/46 | 34/60 |
| **P*** | NS | 0.05 | 0.08 | 0.03 | 0.02 | NS | NS | NS | 0.04 |

*LOH at one or both markers. *P*-values based on logistic regression adjusting for p53 mutational status, smoking status, age and gender. NS — not significant.
allelic deletions were more frequent in squamous cell carcinomas for most loci. After adjusting for p53 mutational status, smoking, gender and age the difference between the two subtypes became significant for the 3p, 5q and 17p regions. Different pattern of genetic changes have previously been reported for the 2 histological types (Sato et al, 1994). We have also found a significantly higher frequency of p53 mutations in squamous cell carcinomas than adenocarcinomas (Kure et al, 1996; Skauk et al, 2000). The development of different histological types of lung tumours has been suggested to reflect a dose effect of tobacco carcinogens. More centrally located cells of the airways giving rise to squamous cell carcinomas are exposed to a greater carcinogen concentration than more distal cells giving rise to the more peripherally located adenocarcinomas (Burke et al, 1998).

Our data indicate that LOH at 3p, 5q, 9p, 11p and 17p regions, often affected in NSCLC, are interdependent and highly associated with mutated p53 gene. Compounds in the tobacco smoke in addition to clonal selection may be the driving force in these alterations.

ACKNOWLEDGEMENTS

We thank Ms Rita Baera for excellent technical assistance and Dr Lodve Stangeland for providing lung tissue and patient data. This project was supported by The Norwegian Research Council, The Norwegian Cancer Society and EU grant ENV4-CT97-0469.

REFERENCES

Albertoni M, Daub DM, Arden KC, Viers CS, Powell C and Van Meir EG (1998) Genetic instability leads to loss of both p53 alleles in a human glioblastoma. Oncogene 16: 321–326

Benachenhou N, Guiral S, Gorska-Flipot I, Labuda D and Sinnett D (1999) Frequent microsatellite instability in tumors of non-smoking subjects: analysis of lung tumours of non-smoking subjects: relationship to gender and lung DNA adduct levels. Int J Cancer 78: 73–78

Meeked KL, Tang W, Kachnic LA, Luo CM, DeFrank JS and Powell SN (1997) Inactivation of p53 results in high rates of homologous recombination. Oncogene 14: 1847–1857

Mellon I, Rajpal DK, Koi M, Boland CR and Champhe GN (1996) Transcription-coupled repair deficiency and mutations in human mismatch repair genes. Science 272: 557–560

Meyers M, Theodosiou M, Acharya S, Odgaard E, Wilson T, Lewis JE, Davis TW, Wilson-Van PC, Fishel R and Boothman DA (1997) Cell cycle regulation of the human DNA mismatch repair genes hMLH2, hMLH1, and hPMS2. Cancer Res 57: 206–208

Mitsudomi T, Ohmura K, Ohno S, Kojima T, Tsuruo T, Yasumoto K, Tanaka N, Gomi K, Ohno S, Tone Y, Kikuchi K, Ogawa T, Sato T, Hashimoto T, Furuta Y, Ikeda T, Sano H, Asamura H, Hirao K, Yokota J and Miyagawa T (2000) Activating mutations in the EML4 gene in non-small-cell lung cancer. Nature 408: 533–537

Miyazaki M, Takahashi T, Tanaka H, Tsuchiya T, Ueda Y, Ito H, Kawasaki Y, Fujimoto A, Yamada T, Nakamura K, Nakamura Y, Yokota J and Ueda R (1993) The frequency of p53 mutations in tumours of non-smoking subjects. Int J Cancer 52: 861–865

Mitchell RS, Broudy JH, Turpin JB, Takashima J, Suchard MA, Powell C and Van Meir EG (1998) Expression of the human hMLH1 and hMSH2 genes in non-small cell lung cancer. Cancer Res 58: 4196–4199

Molenaar WC, Steenwinckel W, Heijenbrok K, van der Pluijm S, Neven P, van der Velden J, de Vries C, Beerthuizen H, Oosterhuis JW, Horlings HM and van der Burg S (2001) Mutations of the DNA mismatch repair genes hMLH1 and hMSH2 in primary colorectal cancer. Int J Cancer 94: 653–659
Pellegrini S, Bertacca G, Buttitta F, Bevilacqua G and Marchetti A (1999) Lung tumours from non-smoking subjects: A p53-related genetic instability in a subset of cases. Int J Mol Med 4: 419–424

Ryberg D, Hewer A, Phillips DH and Haugen A (1994a) Different susceptibility to smoking-induced DNA damage among male and female lung cancer patients. Cancer Res 54: 5801–5803

Ryberg D, Kure E, Lystad S, Skaug V, Stangeland L, Mercy I, Borresen AL and Haugen A (1994b) p53 mutations in lung tumors: relationship to putative susceptibility markers for cancer. Cancer Res 54: 1551–1555

Sato S, Nakamura Y and Tsuchiya E (1994) Difference of allelotype between squamous cell carcinoma and adenocarcinoma of the lung. Cancer Res 54: 5652–5655

Schreiber G, Fong KM, Peterson B, Johnson BE, O’Briant KC and Bepler G (1997) Smoking, gender, and survival association with allele loss for the LOH11B lung cancer region on chromosome 11. Cancer Epidemiol Biomarkers Prev 6: 315–319

Skaug V, Ryberg D, Kure EH, Arab MO, Stangeland L, Myking AO and Haugen A (2000) p53 mutations in defined structural and functional domains are related to poor clinical outcome in non-small cell lung cancer patients. Clin Cancer Res 6: 1031–1037

Sozzi G, Sard L, De Gregorio L, Marchetti A, Musso K, Buttitta F, Tornielli S, Pellegrini S, Veronese ML, Manenti G, Incarbone M, Angeletti CA, Pastirino U, Huebner K, Bevilaqua G, Pilotti S, Croce CM and Pierotti MA (1997) Association between cigarette smoking and Fhit gene alterations in lung cancer. Cancer Res 57: 2121–2123

Takagi Y, Osada H, Karoriishi T, Mitasudomi T, Kondo M, Nizami T, Saji S, Gazdar AF, Takahashi T and Minna JD (1998) p53 mutations in non-small-cell lung cancers occurring in individuals without a past history of active smoking. Br J Cancer 77: 1568–1572

Todd S, Franklin WA, Varella-Garcia M, Kennedy T, Hahner L, Anderson M, Wiest JS, Drabkin HA and Gemmill RM (1997) Homozygous deletions of human chromosome 3p in lung tumors. Cancer Res 57: 1344–1352

Tomizawa Y, Nakajima T, Kohno T, Saito R, Yamaguchi N and Yokota J (1998) Clinicopathological significance of Fhit protein expression in stage I non-small cell lung carcinoma. Cancer Res 58: 5478–5483

Walker DR, Bond JP, Tarone RE, Harris CC, Makalowski W, Boguski MS and Greenblatt MS (1999) Evolutionary conservation and somatic mutation hotspot maps of p53: correlation with p53 protein structural and functional features. Oncogene 18: 211–218

Wei Q and Spitz MR (1997) The role of DNA repair capacity in susceptibility to lung cancer: a review. Cancer Metastasis Rev 16: 295–307

Wei Q, Cheng L, Hong WK and Spitz MR (1996) Reduced DNA repair capacity in lung cancer patients. Cancer Res 56: 4103–4107

Wei Q, Eicher SA, Guan Y, Cheng L, Xu J, Young LN, Saunders KC, Jiang H, Hong WK, Spitz MR and Strom SS (1998) Reduced expression of hMLH1 and hGTBP/hMSH6: a risk factor for head and neck cancer. Cancer Epidemiol Biomarkers Prev 7: 309–314

Wistuba II, Montellano FD, Milchgrub S, Virmani AK, Behrens C, Chen H, Ahmadian M, Nowak JA, Muller C, Minna JD and Gazdar AF (1997) Deletions of chromosome 3p are frequent and early events in the pathogenesis of uterine cervical carcinoma. Cancer Res 57: 3154–3158

Wistuba II, Behrens C, Milchgrub S, Bryant D, Hung J, Minna JD and Gazdar AF (1999) Sequential molecular abnormalities are involved in the multistage development of squamous cell lung carcinoma. Oncogene 18: 643–650

Wu X, Zhao Y, Honn SE, Tomlinson GE, Minna JD, Hong WK and Spitz MR (1998) Benzo[a]pyrene diol epoxide-induced 3p21.3 aberrations and genetic predisposition to lung cancer. Cancer Res 58: 1605–1608

Yin Y, Tainsky MA, Bischoff FZ, Strong LC and Wahl GM (1992) Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell 70: 937–948